Filing Flows › Comparisons › MRK vs SNY
Merck vs Sanofi: MRK and SNY compared
Merck is the larger company: $18.1B of revenue in its latest quarter (Q3 2026) against $14.4B for Sanofi (Q3 2026). Sanofi is growing faster (+16% against +5% a year earlier). Merck is more profitable, with an operating margin of 30.7% against 30.1%.
Where the money goes: MRK and SNY
Merck (MRK) · Q3 2026
Merck, Q3 2026: revenue $18.1B (+5% year over year), operating margin 30.7%, net earnings $5.1B, operating cash flow $6.6B. The chart follows the revenue to costs, profit and cash.
Sanofi (SNY) · Q3 2026
Sanofi, Q3 2026: revenue $14.4B (+16% year over year), operating margin 30.1%, net earnings $3.0B. The chart follows the revenue to costs, profit and cash.
| Merck (MRK) | Sanofi (SNY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $18.1B | $14.4B |
| Revenue growth, Y/Y | +5% | +16% |
| Gross margin | — | 80.3% |
| Operating margin | 30.7% | 30.1% |
| Net earnings | $5.1B | $3.0B |
| Net margin | 28.0% | 21.0% |
| Operating cash flow | $6.6B | — |
| Free cash flow | $5.5B | — |
| Market value | $363.6B | — |
| P/E | 151.3× | — |
| Analysts’ mean target | $161.53 | — |
Where the revenue comes from
Sanofi
- Sales at constant exchange rates: $14.2B (98%)
- Effect of exchange rates: $228M (2%)
Questions
Which is bigger, Merck or Sanofi?
Merck is the larger company: $18.1B of revenue in its latest quarter (Q3 2026) against $14.4B for Sanofi (Q3 2026).
Is Merck or Sanofi growing faster?
Sanofi is growing faster (+16% against +5% a year earlier).
Which is more profitable, Merck or Sanofi?
Merck is more profitable, with an operating margin of 30.7% against 30.1%.
More: Merck earnings · how Merck makes money · Sanofi earnings · how Sanofi makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 6-K filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.